MAIA Biotechnology (MAIA) director reports stock and option purchases

Rhea-AI Filing Summary

MAIA Biotechnology, Inc. director Louie Ngar Yee reported an insider purchase of common stock and related stock options. On 12/22/2025, the director acquired 81,699 shares of common stock at $1.224 per share pursuant to a Securities Purchase Agreement, bringing total directly held common shares to 1,248,888.

On the same date, the director also acquired stock options on 81,699 shares with an exercise price of $1.36 per share. These options, deemed options under the company’s 2021 Equity Incentive Plan, become exercisable on 06/22/2026 and expire on 12/22/2028. Following these transactions, the director beneficially owns 81,699 derivative securities in addition to the common stock holdings.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Louie Ngar Yee

(Last) (First) (Middle)

444 WEST LAKE STREET, SUITE 1700

(Street)

CHICAGO IL 60606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/22/2025		P		81,699(1)	A	$1.224	1,248,888	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$1.36	12/22/2025		P		81,699(2)		06/22/2026	12/22/2028	Common Stock	81,699	$1.36	81,699	D

Explanation of Responses:

1. The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on December 22, 2025

2. These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on December 22, 2025. The options are exercisable beginning on the six month anniversary of the issuance date and expire 3-years after the initial issuance date.

	/s/ Louie Ngar Yee	12/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MAIA (MAIA) report in this Form 4?

A director of MAIA Biotechnology, Inc., Louie Ngar Yee, reported buying 81,699 shares of common stock and acquiring stock options for 81,699 shares on 12/22/2025.

At what prices were the MAIA common shares and options acquired?

The director purchased 81,699 common shares at $1.224 per share and acquired stock options with an exercise price of $1.36 per underlying share.

How many MAIA shares does the director own after this transaction?

After the reported purchase, the director beneficially owns 1,248,888 shares of MAIA common stock, held directly, plus 81,699 derivative securities in the form of stock options.

When can the MAIA stock options reported in this filing be exercised?

The reported stock options on 81,699 shares become exercisable on 06/22/2026 and expire on 12/22/2028, three years after the initial issuance date.

Under what arrangements were the MAIA shares and options issued?

The common stock was purchased under a Securities Purchase Agreement and issued under MAIA’s 2021 Equity Incentive Plan. The warrants from the same agreement were deemed stock options under that plan.

What is the reporting person’s relationship to MAIA Biotechnology?

The reporting person, Louie Ngar Yee, is identified as a director of MAIA Biotechnology, Inc. and filed the Form 4 as a single reporting person.